Evidence map›Paper›PMID 36102322›Full record

ArticleOncology reports2022

Romina Armando, Maia Cabrera, Roman Vilarullo, Patricio Chinestrad, Julian Maggio, Camila Paderta, Pablo Lorenzano Menna, Daniel Gomez, Diego Mengual Gómez

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Romina ArmandoMolecular Oncology Unit, Center of Molecular and Translational Oncology, Quilmes National University, Bernal, Buenos Aires B1876BXD, Argentina.
Maia CabreraLaboratory of Molecular Pharmacology, Quilmes National University, Bernal, Buenos Aires B1876BXD, Argentina.
Roman VilarulloMolecular Oncology Unit, Center of Molecular and Translational Oncology, Quilmes National University, Bernal, Buenos Aires B1876BXD, Argentina.
Patricio ChinestradLaboratory of Molecular Pharmacology, Quilmes National University, Bernal, Buenos Aires B1876BXD, Argentina.
Julian MaggioMolecular Oncology Unit, Center of Molecular and Translational Oncology, Quilmes National University, Bernal, Buenos Aires B1876BXD, Argentina.
Camila PadertaMolecular Oncology Unit, Center of Molecular and Translational Oncology, Quilmes National University, Bernal, Buenos Aires B1876BXD, Argentina.
Pablo Lorenzano MennaLaboratory of Molecular Pharmacology, Quilmes National University, Bernal, Buenos Aires B1876BXD, Argentina.
Daniel Gomez *Molecular Oncology Unit, Center of Molecular and Translational Oncology, Quilmes National University, Bernal, Buenos Aires B1876BXD, Argentina.
Diego Mengual Gómez *Molecular Oncology Unit, Center of Molecular and Translational Oncology, Quilmes National University, Bernal, Buenos Aires B1876BXD, Argentina.
National University of Quilmes · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor cells have unlimited replicative potential, principally due to telomerase activity, which requires assembly of components such as dyskerin (hDKC1), human telomerase reverse transcriptase and human telomerase RNA (hTR). The present study aimed to develop novel inhibitors of telomerase to target the interaction between hTR and hDKC1. Based on docking‑based virtual screening, the candidates R1D2‑10 and R1D2‑15, which exert an

Indexed as

Breast NeoplasmsTelomeraseApoptosisFemaleHumansMCF-7 CellsRNA-Binding ProteinsRNA-Binding ProteinsTelomeraseabsorptionanalog designbreast cancerchemical diversitydistributiondyskerinexcretion propertieshuman telomerase RNAmetabolismtelomerase

Identifiers

PMID36102322
PMCPMC9500588
OpenAlexW4295750769

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.